ContractCollaboration Agreement • May 5th, 2020
Contract Type FiledMay 5th, 2020[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit 10.12 AMENDMENT TO COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND BAYER CORPORATION This Amendment to the Collaboration Agreement (the “Second Amendment”) is dated February 1, 1999 (“the Effective Date of the Second Amendment”) by and between ONYX PHARMACEUTICALS, Inc., a California corporation having its principal place of business in Richmond, California (“Onyx”) and BAYER CORPORATION, an Indiana corporation having its principal place of business in Pittsburgh, Pennsylvania (“Bayer”). Bayer and Onyx may be referred to herein individually as “Party,” or collectively, as the “Parties.” Recitals Whereas, Onyx and Bayer (under the name Miles Inc., the prior name of Bayer) entered into a Collaboration Agreement dated April
AMENDMENT TO COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND BAYER CORPORATIONCollaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 10th, 2006 Company IndustryThis Amendment to the Collaboration Agreement (the “Second Amendment”) is dated February 1, 1999 (“the Effective Date of the Second Amendment”) by and between ONYX PHARMACEUTICALS, Inc., a California corporation having its principal place of business in Richmond, California (“Onyx”) and BAYER CORPORATION, an Indiana corporation having its principal place of business in Pittsburgh, Pennsylvania (“Bayer”). Bayer and Onyx may be referred to herein individually as “Party,” or collectively, as the “Parties.”